Invested in
Apyx Medical?
Contact investor lawyers for a free evaluation of your potential claims for compensation today.
- Are you an investor in Apyx Medical Corporation (NASDAQ: APYX)?
- Are you concerned about the allegations of misleading statements and/or omissions surrounding Apyx’s J-Plasma technology?
- Are you concerned about the performance of the APYX stock price?
- Would you like your potential options for compensation and/or redress to be reviewed by an experienced team of investor lawyers?
Request a free case evaluation via email at arosca@rscounsel.law, leave a message through the contact form on this page, or call us at 888-998-0530.
Contact Us About Your
Investments
Free Case Evaluation
The Apyx Medical Corporation Investor Center is the Resource for Investors Who Invested in Apyx Medical Corporation Shares.
- Free Case Evaluation
- No Fees if No Recovery
- Contact Us Today
We can also do a Zoom call to discuss your matter.
Posted July 26, 2022
Apyx Medical Investigation
Securities attorneys Alan Rosca and Paul Scarlato have been investigating potential securities violations, corporate misconduct, and questionable business practices and misrepresentations involving Apyx and have identified potential areas of concern.
APYX stock investors interested to evaluate potential options to seek compensation and/or pursue claims related to their Apyx Medical holdings may contact investor rights attorneys Alan Rosca and Paul Scarlato. Attorneys Rosca and Scarlato have extensive experience in seeking compensation related to investor harm and pursuing claims arising out of corporate misconduct and are currently evaluating potential claims on behalf of investors in Apyx They typically work on a contingent fee basis, do not require any money down from their clients, advance case expenses, and only get paid for their fees and expenses if and when successful, pursuant to court review and approval.
Claims that are not timely pursued may expire or otherwise be lost, generally speaking. Apyx Medical investors interested to explore options to file claims should consider taking action promptly.
Concerned APYX stock stock investors investors may contact attorneys Alan Rosca or Paul Scarlato to discuss their potential options toll free at 888-998-0530, via email at arosca@rscounsel.law, or through the contact form on this webpage.
About Apyx Medical
Apyx Medical Corporation is a Delaware advanced energy technology company incorporated in 1982, with offices in Clearwater, Florida. Apyx reportedly designs, develops and manufactures electrosurgical equipment, with a focus on the cosmetic surgery market. The company’s stated mission is “To be the world’s leading innovator in unique energy solutions that transform physicians’ practices and patients’ lives.”
One of the marketed technologies developed by Apyx Medical Corporation is reportedly called J-Plasma, an energy modality reportedly designed to allow surgeons to use the energy on and around sensitive structures. According to Apyx marketing materials, J-Plasma is the technology behind Renuvion Cosmetic Technology, a procedure reportedly used in dermal resurfacing Procedures.
According to its website and regulatory filings, Apyx Medical Corporation is currently led by a management team that lists Charles D. Goodwin as President and Chief Executive Officer, Tara Semb as Chief Financial Officer, Moshe Citronowicz as Senior Vice President, and Todd Hornsby as Executive Vice President.
Apyx Medical commons shares are listed on Nasdaq under the symbol “APYX”. On July 22, 2022 the price per APYX share was $9.05, in decline compared to November 22, 2021 when it reached $17.40 per share, according to data from Google Finance.
Apyx Medical Corporation Class Action Complaints
In April 2019, Apyx Medical Corporation investors filed a class action complaint alleging violations of securities law in connection to certain materially false and/or misleading statements, as well as alleged failure to disclose surrounding the use of the J-Plasma technology for dermal resurfacing.
In June 2020 the parties to the Apyx class action filed a Notice of Settlement and the case was concluded a year later, in June 2021.
Additionally, a new class action case has recently been filed against Apyx Medical Corporation, Charles D. Goodwin II, and Tara Semb, on June 6, 2022.
The complaint alleges wrongful acts and omissions regarding the number of off label uses of Apyx’s Advanced Energy products, that allegedly led to the increase of number of medical device reports filed by Apyx reporting serious adverse events exposing Apyx to regulatory scrutiny.
According to the complaint, on Mach 14, 2022, Apyx reportedly issued a press release announcing that the company was “notified of pending FDA medical device safety communication related to its Advanced Energy products.” The press release further clarified that Apyx believes that the FDA’s communication will pertain to the “use of Advanced Energy products outside of their FDA-cleared indication.” The news allegedly had a negative impact on the price per APYX share, reportedly causing it to fall over $4, or more that 40% to close at $5.88 per share on March 14, 2022.
As a result, the plaintiffs requested compensatory damages plus interest, costs, and expenses, to include attorney fees and expert fees. As of July 26, 2022 the lawsuit is shown as pending.
Potential Compensation Claims
Concerned About Your Apyx Medical Corporation Investment?
Investor rights attorneys Alan Rosca and Paul Scarlato at Rosca Scarlato LLC are investigating potential options and are evaluating potential claims on behalf of APYX shareholders. They have decades of combined experience representing victims of corporate or financial misconduct.
If you are an Apyx Medical investor concerned about your investment, you may contact attorneys Alan Rosca or Paul Scarlato to learn more about your rights and for an evaluation of your case, or to provide useful information. All consultations are free. The Rosca Scarlato LLC attorneys typically take cases like this on a contingency fee basis, advance all case costs, and only get paid for their fees and expenses if and when they are successful, following review and approval by the Court of any fee application.
To reach attorney Alan Rosca or his colleagues, Apyx Medical investors may call 888-998-0530, email arosca@rscounsel.law, or leave a message through the contact form on this webpage.
These general considerations are for informational purposes only and do not constitute legal advice. Such legal advice can only be offered once the attorneys discuss each investor’s situation, learn of the relevant facts and can tailor any advice to that investor’s facts. Apyx Medical investor center is not affiliated with Apyx Medical Corporation.
Contact info:
Rosca Scarlato LLC – 216-946-7070 / 888-998-0530.
Alan Rosca – arosca@rscounsel.law
Paul Scarlato – pscarlato@rscounsel.law
Recent Investigations
- Posted on
- Posted on
DISCLAIMER
In our legal system, every person is innocent until and unless found guilty by a court of law or a tribunal. Whenever we reference “allegations” or charges that are “alleged,” such allegations or charges have not been proven, and are merely accusations, not findings of fault, as of the date of the blog. We do not have, nor do we undertake, a duty to continue to monitor or follow matters about which we report, and/or to publish subsequent updates regarding various developments that may occur in such matters. Readers are encouraged to conduct their own research regarding any such matters and any developments that may or may not have occurred in such matters. Also, the Brokercheck report linked to some of our blogs is the up-to-date version as of the date of accessing by the reader. The information in our blogs is current as of the date of the drafting of the blog, and given that sometimes certain past complaints may no longer be listed in newer Brokercheck reports, some of the events referenced in some of our blogs may later on be removed from newer Brokercheck reports. Visitors may check the most recent version of each brokercheck report at www.finra.org, and may contact FINRA for the earlier version of the Brokercheck report upon which various blogs may be based.